| Quarter (USD) | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| 13F holders | Current |
|---|---|
| Total holders | 286 |
| Opened positions | 40 |
| Closed positions | 53 |
| Increased positions | 101 |
| Reduced positions | 90 |
| 13F shares | Current |
|---|---|
| Total value | 898.62 bn |
| Total shares | 71.98 mm |
| Total puts | 35.10 k |
| Total calls | 1.72 mm |
| Total put/call ratio | 0.0 |
| Largest owners | Shares | Value |
|---|---|---|
| Capital Research Global Investors | 13.16 mm | $174.27 bn |
| MS Morgan Stanley | 5.60 mm | $74.15 bn |
| GS The Goldman Sachs Group, Inc. | 4.63 mm | $61.28 bn |
| Arrowstreet Capital, Limited Partnership | 4.22 mm | $55.82 bn |
| FMR | 3.39 mm | $44.83 bn |
| First Trust Advisors | 3.24 mm | $42.91 bn |
| Renaissance Technologies | 3.08 mm | $40.77 bn |
| Brandes Investment Partners | 3.04 mm | $40.24 bn |
| Van Eck Associates | 2.21 mm | $29.27 mm |
| BlackRock | 2.20 mm | $29.18 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 24 Jan 24 | Takeda Pharmaceutical Company Limited | Common Stock | Sell | Dispose S | No | No | 8.1 | 3,703,703 | 30.00 mm | 3,755,583 |
